By Dani Kass ( January 16, 2024, 9:49 PM EST) -- Pfizer and BioNTech have told the Patent Trial and Appeal Board not to rely on the timing of district court patent litigation to reject their challenges to a pair of Moderna COVID vaccine patents, arguing that the company relied on "cherry-picked data" and is acting "willfully naïve."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.